L-Dopa decarboxylase (DDC) constitutes an emerging biomarker in predicting patients’ survival with stomach adenocarcinomas

Citation:

Florou D, Papadopoulos IN, Fragoulis EG, Scorilas A. L-Dopa decarboxylase (DDC) constitutes an emerging biomarker in predicting patients’ survival with stomach adenocarcinomas. Journal of cancer research and clinical oncology. 2013;139:297–306.

Contact Details

National and Kapodistrian University of Athens, University General Hospital 'Attikon', Fourth Surgery Department,
Mobile +30 6944 661 484

Athens, ZipCode 12462
ipapado@med.uoa.gr
ina.papadopoulos@gmail.com

<embed>

Recent Publications

Enhanced miR-182 transcription is a predictor of poor overall survival in colorectal adenocarcinoma patients
Femoral fractures are an indicator of increased severity of injury for road traffic collision victims: an autopsy–based case–control study on 4895 fatalities
Heat shock protein beta 3 (HSPB3) is an unfavorable molecular biomarker in colorectal adenocarcinoma

Submitted (1)
2021 (1)
2020 (5)
2019 (1)
2018 (5)
2017 (17)
2016 (4)
2015 (3)
2014 (20)
2013 (12)

Iordanis Papadopoulos

Professor, Medicine

L-Dopa decarboxylase (DDC) constitutes an emerging biomarker in predicting patients’ survival with stomach adenocarcinomas

Citation:

Contact Details

Recent Publications

Publications per year